ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1434	National Cancer Institute	Html	en	Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.	CLL 0.563454 German CLL Study 0.551069 monoclonal B-cell lymphocytosis 0.528403 Engl J Med 0.555252 trial 0.525679 leukemia group 0.552678 M. Prolymphocytic leukemia 0.545972 Routine chronic administration 0.534661 lymphocytic leukemia patients 0.591222 Leukemia group B. 0.542105 CLL Study Group 0.54078 cyclophosphamide 0.529502 Byrd JC 0.527428 Keating MJ 0.535835 advanced chronic 0.539233 patients 0.592663 Lymphocytic Leukemia Study 0.593872 T-cell prolymphocytic leukemia 0.546745 refractory high-risk chronic 0.534243 refractory chronic 0.528565 Adult Leukemia Group 0.542021 Leuk Lymphoma 0.531402 Lymphocytic Leukemia section 0.595648 fludarabine 0.547348 alemtuzumab versus fludarabine 0.527105	untreated B chronic 0.530625 et al. 0.648755 treatment 0.535273 small lymphocytic lymphoma 0.590269 French Cooperative Group 0.528743 German Chronic Lymphocytic 0.583925 Relapsed Chronic Lymphocytic 0.579501 acute myeloid leukemia 0.53754 stem cell 0.529413 Leukemia Study Group 0.55235 rituximab 0.530116 fludarabine-refractory B-cell chronic 0.53547 CLL therapy 0.52689 chronic lymphoid leukemia 0.573599 CLL Study Group. 0.526303 Abstract 0.627578 therapy 0.53011 Clin Oncol 0.713099 hairy cell leukemia 0.553353 blood 0.56117 chronic lymphocytic leukemia 0.965039 chronic lymphocytic leukaemia 0.705583 previously untreated patients 0.578343 allogeneic stem cell 0.525551	CLICK HERE
1870	National Cancer Institute	Html	es	Tratamiento de los tumores de células germinativas del ovario (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores de células germinativas del ovario.	germ-cell tumors 0.421459 germ-cell tumors with 0.411803 Obstet Gynecol 0.406415 ovarian germ 0.634072 malignant germ 0.435096 endodermal sinus tumor 0.403615 cell tumors treated 0.404749 Liao SY 0.410388 Adjuvant therapy 0.410358 Gershenson DM 0.467949 Current therapy 0.403318 Williams SD 0.494559 tumores malignos mixtos 0.404882 Hacker NF 0.402853 Instituto Nacional 0.403668 high-dose chemotherapy 0.403104 or etoposide 0.404727 DiSaia PJ 0.408704 Moore DH 0.407371 University Medical Center 0.403543 quimioterapia postoperatoria 0.403765 Gynecol Oncol 0.453558 pacientes jóvenes 0.408368 lavados peritoneales 0.410402 New York University 0.403494	Icb Tumor 0.403092 gynecologic oncology group 0.703201 Blessing JA 0.51199 Birch R 0.404259 estadio iv 0.424378 Einhorn LH 0.40484 Dembo AJ 0.402909 estadio ia 0.408575 ovary with 0.410468 Morris M 0.407706 with advanced germ 0.403782 IIIa Tumor 0.403067 York University Medical 0.403528 Intern Med 0.411687 second-look laparotomy 0.431921 Clin Oncol 0.539728 estadio iii 0.41476 cell tumors using 0.405334 tumor macroscópico 0.402814 Oncology Group Study 0.403519 germ cell tumors 0.985883 histerectomía abdominal 0.412918 Cangir A 0.408111 cell tumors with 0.436879	CLICK HERE
1942	National Cancer Institute	Html	es	Tratamiento de las neoplasias mielodisplásicas o mieloproliferativas (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mielodisplásicas o mieloproliferativas, incluso las leucemias mielomonocítica crónica o juvenil y la LMC atípica.	French-American-British Cooperative Leukaemia 0.312371 leucemia mieloide 0.341853 myelomonocytic leukaemia 0.397359 myelomonocytic leukemia with 0.326213 platelet-derived growth factor 0.354049 with juvenile chronic 0.315892 Arber DA 0.312178 health organization classification 0.3281 Leukemia Group 0.315441 genes platelet-derived growth 0.312347 with juvenile 0.340061 chronic myeloid leukemia 0.336615 myelomonocytic leukemia 0.944712 leucemia mielomonocítica 0.387953 chronic myelomonocytic leukemia 0.819447 differentiating myelomonocytic leukemia 0.320578 Beran M 0.312167 World Health Organization 0.355665 neoplasias mielodisplásicas 0.314258 stem cell transplantation 0.313202 chronic myelogenous leukemia 0.364294 Germing U 0.362762 myeloproliferative disorders 0.313394 cases with chronic 0.311538 Leuk Lymphoma 0.332534	myelomonocytic leukemia from 0.33992 chronic myelomonocytic leukaemia 0.386185 juvenile chronic myelogenous 0.347073 marrow transplantation 0.341155 Organización Mundial 0.317633 chronic myeloid 0.357031 Differentiating juvenile myelomonocytic 0.319715 myeloid neoplasms 0.336696 bone marrow transplantation 0.325127 Bennett JM 0.319603 cromosoma filadelfia 0.337822 recuento plaquetario 0.325577 juvenile myelomonocytic leukaemia 0.339361 juvenile myelomonocytic leukemia 0.545157 chronic myeloid leukaemias 0.320258 Clin Oncol 0.32115 Orazi A 0.343564 Cooperative Leukaemia Group 0.311788 atypical chronic 0.319445 características clínicas 0.316309 trastornos mieloides 0.311632 leucemia mieloide aguda 0.316238 with chronic myelomonocytic 0.340508 Emanuel PD 0.350668	CLICK HERE
1946	National Cancer Institute	Html	es	Tratamiento del neuroblastoma (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del neuroblastoma.	glándula tiroides 0.633074 posibles efectos tardíos 0.641796 siguientes procedimientos 0.632822 células madre 0.931788 gen alk 0.612181 siguientes especialistas 0.624871 yodo 131-mibg 0.744725 vía oral 0.649411 rayos x 0.630232 enlace drugs approved 0.631928 estadios 2A 0.624814 niño ayuda 0.632627 ondas sonoras 0.629873 riesgo intermedio 0.674697 efectos tardíos 0.896983 cáncer.ampliar aspiración 0.633221	National Cancer Institute 0.612675 IRMN).Ampliar Imágenes 0.62564 siguientes tratamientos 0.624353 menor producción 0.628805 Instituto Nacional 0.623964 PDQ Tratamiento 0.634123 determinados cambios 0.611022 alta potencia 0.625499 presente sección 0.614217 nuevos tipos 0.61878 sistema nervioso central 0.655496 Physician Data Query 0.650241 siguientes pruebas 0.680017 siguientes estadios 0.629707 siguientes trastornos 0.624626	CLICK HERE
2011	National Cancer Institute	Html	es	Exámenes de detección del cáncer de pulmón (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar o vigilar el cáncer de pulmón.	lung cancer screening 0.491865 Berg CD 0.308884 UK Lung Cancer 0.309828 Cooperative Early Lung 0.306877 Lung Cancer Study 0.310626 lung cancer 0.996403 Reduced lung-cancer mortality 0.308509 American Cancer Society 0.314872 Sloan-Kettering Lung Study 0.306329 Extended lung 0.305748 lung-cancer screening 0.305282 Lung Screening Trial 0.34779 Preventive Services Task 0.315666 early lung cancer 0.370281 Cancer Res 0.308506 screening results 0.305543 exámenes detección 0.3124 Screening Trial 0.41076 lung-cancer mortality with 0.308638 Randomized Danish Lung 0.306065 CT screening 0.322848 Natl Cancer Inst 0.348878 small lung 0.309116 Lung Cancer Risk 0.310447 from baseline screening 0.305357	More lung 0.305626 Screening Trial with 0.311542 early stage lung 0.306471 Is curable lung 0.306471 cytologic screening 0.312546 Hocking WG 0.305973 Hopkins Lung Project 0.306129 CT screening according 0.305575 Danish Lung Cancer 0.338861 Lung Cancer Action 0.32014 randomised danish lung 0.306155 National Lung Screening 0.345051 Intern Med 0.314222 lung cancer detection 0.362796 Services Task Force 0.31539 Randomized Lung Cancer 0.310797 from semi-annual screening 0.30542 PLCO Cancer Screening 0.310194 Mayo Lung Project 0.341943 lung cancers detected 0.306094 Memorial Sloan-Kettering 0.306282 Cancer Action Project 0.310925 Lung Project revisited 0.306785 Cancer Screening Trial 0.390805	CLICK HERE
2064	National Cancer Institute	Html	es	Exposición al asbesto y el riesgo de cáncer	Hoja informativa sobre el asbesto, sobre las enfermedades relacionadas con el asbesto e incluye organizaciones para obtener más información.	técnicos profesionales automotrices 0.5421 gen bap1 0.530949 que familiares de trabajadores 0.533144 normas descritas 0.532666 largo plazo 0.526581 Protección Ambiental 0.672505 World Trade Center 0.546459 principal dependencia 0.532045 Ground Zero 0.529197 derrames pleurales benignos 0.558277 Salud Ocupacional 0.584399 asbesto crisótilo 0.987156 trabajadores portuarios 0.606054 Instituto Nacional 0.563708 menores riesgos 0.533274 Trabajo de EE 0.535904 Employment Standards Administration 0.548898 titulado current best practices 0.543841 Mine Safety 0.535362 sustancias tóxicas 0.635631 siglo xix 0.53032 distintos tipos 0.525229 Estados Unidos 0.992615 automotriz usa 0.531695 Public Affairs 0.529764	serios problemas 0.529441 Environmental Protection Agency 0.815767 línea telefónica tsca 0.556811 Preventing Asbestos Exposure 0.544747 Product Safety Commission 0.67091 Information Division 0.52746 Occupational Safety 0.586355 asbesto causa 0.952053 cuánto tiempo 0.527545 en la mucosidad 0.531534 a las personas 0.529484 posibles peligros 0.5266 Health Administration 0.652906 Consumer Product Safety 0.672282 causa dificultad 0.530297 sumamente bajo. Los fabricantes 0.528798 mejores prácticas 0.574094 Clutch Repair Workers 0.544379 Veterans Affairs 0.528386 Torres Gemelas 0.52642 Compensation Programs 0.5287 Disease Registry 0.526245 Toxic Substances 0.526971 Segunda Guerra Mundial 0.550565	CLICK HERE
3444	National Cancer Institute	Html	es	Exámenes de detección del cáncer de cavidad oral y orofaringe (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de cavidad oral y orofaringe.	Ramadas K 0.326456 Sankaranarayanan R 0.337876 accessed march 0.331249 Zhang L 0.310727 Clinical Preventive Services 0.308765 Interim results from 0.307724 Sin embargo 0.381657 Kerr AR 0.312561 American Cancer Society 0.427439 Early findings from 0.308051 CA Cancer 0.323169 cluster randomized controlled 0.308479 oral pre-malignant 0.326412 oral cancer 0.913191 Preventive Services Task 0.376173 Instituto Nacional 0.317765 Cancer Res 0.323621 Human papillomavirus infection 0.307515 PDQ Exámenes 0.32226 oral cancer screening 0.566684 Estados Unidos 0.310609 Morton TH Jr 0.307383 Morton TH 0.311837 Epstein JB 0.323025 Database Syst Rev 0.307163	visual screening 0.315772 screening with 0.315479 upper aerodigestive tract 0.307566 SEER Cancer Statistics 0.324889 Cancer Society guidelines 0.325639 Trivandrum Oral Cancer 0.343561 carcinoma versus lesiones 0.311231 Jacob BJ 0.31089 potentially malignant disorders 0.308445 Cancer Facts 0.324242 Long term effect 0.3078 adjacent to clinically 0.307949 Oral Oncol 0.526329 oral verrucous 0.325426 National Cancer Institute 0.351683 center grapples with 0.307601 Oral Pathol Med 0.361585 Screening Study Group 0.316915 Am Dent Assoc 0.308416 Services Task Force 0.375429 Fluorescence visualization detection 0.308258 detección versus atención 0.319469 Brief Evidence Update 0.307856 Poh CF 0.312257	CLICK HERE
3460	National Cancer Institute	Html	es	Coenzima Q10 (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de la coenzima Q10 como tratamiento para las personas con cáncer.	Natl Acad Sci 0.506232 animal models 0.503048 Lockwood K 0.522246 Friend leukemia virus 0.50335 Mol Aspects Med 0.525442 Prog Drug Res 0.505422 Exp Clin Res 0.507107 Ernster L 0.506157 Clin Investig 0.504327 vitamina q10 0.508703 vitamin q10 0.549224 Health Syst Pharm 0.503499 Chem Pathol Pharmacol 0.515808 Bliznakov EG 0.512562 Hanioka T 0.504235 coenzyme q10 0.845306 with vitamin q10 0.522905 reticuloendothelial system upon 0.50329 Res Commun Chem 0.525595 coenzima q10 0.990386 Nylander M 0.503126 system upon stimulation 0.503357 coenzima q.10 0.50372 Coenzyme Q10 administration 0.515239 patients with 0.52239	Clinical Aspects 0.506167 Folkers K 0.720923 patients treated with 0.503528 Osterborg A 0.503093 coenzima q10 resumen 0.509859 Commun Chem Pathol 0.52121 Moesgaard S 0.509545 Biophys Res Commun 0.66246 Chemother Rep 0.503476 Nordenbrand K 0.502764 Proc Natl Acad 0.506461 Apparent partial remission 0.503092 Biochem Biophys Res 0.653978 with nutritional antioxidants 0.504649 coenzima q10 ayuda 0.51293 Drugs Exp Clin 0.50459 conzima q10 0.506965 Overvad K 0.504381 Clin Nutr 0.503026 serious deficiency 0.503488 coenzyme q10 concentrations 0.523415 radicales libres 0.504036 essential fatty acids 0.503269 Yamashita S 0.503124	CLICK HERE
15639	National Cancer Institute	Html	null	Grants	Learn about the different grants that are available, such as Research Projects Grants, SPORE Grants, career awards and cancer education grants, training grants, and others.			CLICK HERE
16842	National Cancer Institute	Html	en	Johns Hopkins University — Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer Research	The focus of the Johns Hopkins University Cancer Nanotechnology Training Center is presented here.	predoctoral fellows 0.736483 cancer nanobiotechnology 0.632531 optimal treatment 0.545276 Johns Hopkins University 0.729715 journal club 0.539106 novel cancer diagnostics 0.713403 program fosters 0.562779 steady state number 0.670018 epigenetic markers 0.560601 tumor boards 0.538166 NTCR program 0.576419 new frontier 0.564875 individual patient 0.643505 engineering/physics discipline 0.563571 physical sciences-oncology center 0.676488 lab course 0.540911 new modalities 0.563 cellular / cancer 0.59221 Johns Hopkins Institute 0.669855 dedicated annual symposium 0.651728 experimental facilities 0.538368 Vivo Cellular 0.548936 Molecular Imaging Center 0.688968 black-box input-output techniques 0.710638	scientific exploration 0.554225 clinical resources 0.5443 human diseases 0.555299 cancer cell functions 0.720912 clinical conferences 0.540551 high-throughput diagnostic tools 0.682779 non-viral delivery systems 0.686087 unique educational resources 0.657197 postdoctoral fellows 0.715577 Principal Investigator 0.564913 therapeutic tools 0.551025 Pancreatic Cancer Center 0.731915 Ludwick Center 0.581555 NTCR trainees 0.59515 cancer nanotechnology excellence 0.742492 outstanding trainees 0.578764 disease phenotype 0.55677 Comprehensive Cancer Center 0.727928 Cancer Genetics 0.585039 NTCR fellows 0.742981 engineer novel drug/antibody/siRNA 0.668859 human cancers 0.551276 core courses 0.541397 Training Focus 0.565904	CLICK HERE